Literature DB >> 8664050

Photodynamic effects of 5-aminolevulinic acid-induced porphyrin on human bladder carcinoma cells in vitro.

R Riesenberg1, C Fuchs, M Kriegmair.   

Abstract

The efficiency of 5-aminolevulinic acid (ALA) in photodynamic therapy (PDT) was investigated in vitro using urothelial carcinoma cells of various differentiation. HCV29, RT4 and J82 cells were cultured in 96-well plates, incubated with 25-100 micrograms/ml ALA in serum-containing medium for 4 h, and irradiated at 630, 635 and 640 nm wavelength with light doses of 15-100 J/cm2. The degree of reduced tetrazolium bromide corresponding to cell viability was determined with a colorimetric MTT assay 0, 24 and 48 h after PDT. A remarkable reduction of mitochondrial activity occurred in poorly (J82) and well differentiated (RT4) malignant urothelial cells. Twenty-four hours after photodynamic treatment with 100 micrograms/ml ALA and 50 J/cm2, the metabolic activity of malignant cells was nearly extinguished, while HCV29 cells, derived from normal urothelium, behaved similarly to non-irradiated control cells. The photosensitivity of cells depended on presence or absence of fetal bovine serum (FBS) in the ALA-incubation medium. A wavelength of 635 nm was up to 60% more effective compared with 630 nm, which is more frequently applied in PDT. From the results of our in vitro studies, we can define a "therapeutic window" for malignant cells without damaging benign cells. The time delayed effects and the strong wavelength dependence are important factors for a clinical application.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8664050     DOI: 10.1016/0959-8049(95)00548-x

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  8 in total

1.  Specific intensity imaging for glioblastoma and neural cell cultures with 5-aminolevulinic acid-derived protoporphyrin IX.

Authors:  Frank Duffner; Rainer Ritz; Dirk Freudenstein; Michael Weller; Klaus Dietz; Johannes Wessels
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

2.  Effect of photodynamic therapy in combination with mitomycin C on a mitomycin-resistant bladder cancer cell line.

Authors:  S N Datta; R Allman; C Loh; M Mason; P N Matthews
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

3.  Photodynamic diagnosis of breast tumours after oral application of aminolevulinic acid.

Authors:  D P Ladner; R A Steiner; J Allemann; U Haller; H Walt
Journal:  Br J Cancer       Date:  2001-01-05       Impact factor: 7.640

4.  Multi-modality therapeutics with potent anti-tumor effects: photochemical internalization enhances delivery of the fusion toxin scFvMEL/rGel.

Authors:  Pål K Selbo; Michael G Rosenblum; Lawrence H Cheung; Wendy Zhang; Kristian Berg
Journal:  PLoS One       Date:  2009-08-19       Impact factor: 3.240

5.  In vitro comparison of hypericin and 5-aminolevulinic acid-derived protoporphyrin IX for photodynamic inactivation of medulloblastoma cells.

Authors:  Rainer Ritz; Christian Scheidle; Susan Noell; Florian Roser; Martin Schenk; Klaus Dietz; Wolfgang S L Strauss
Journal:  PLoS One       Date:  2012-12-14       Impact factor: 3.240

6.  Differentiation-specific increase in ALA-induced protoporphyrin IX accumulation in primary mouse keratinocytes.

Authors:  B Ortel; N Chen; J Brissette; G P Dotto; E Maytin; T Hasan
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

7.  Loss of MTUS1/ATIP expression is associated with adverse outcome in advanced bladder carcinomas: data from a retrospective study.

Authors:  Anja Rogler; Sabine Hoja; Johannes Giedl; Arif B Ekici; Sven Wach; Helge Taubert; Peter J Goebell; Bernd Wullich; Michael Stöckle; Jan Lehmann; Sabrina Petsch; Arndt Hartmann; Robert Stoehr
Journal:  BMC Cancer       Date:  2014-03-20       Impact factor: 4.430

Review 8.  Systematic Review and Meta-Analysis of In Vitro Anti-Human Cancer Experiments Investigating the Use of 5-Aminolevulinic Acid (5-ALA) for Photodynamic Therapy.

Authors:  Yo Shinoda; Daitetsu Kato; Ryosuke Ando; Hikaru Endo; Tsutomu Takahashi; Yayoi Tsuneoka; Yasuyuki Fujiwara
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.